ArticleCancer cell international2015
Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression.
Article in Cancer cell international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 49 citations in OpenAlex.
- Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis.British journal of cancer · 2025Article
- Suramin, an antiparasitic drug, stimulates adipocyte differentiation and promotes adipogenesis.Lipids in health and disease · 2023Article
- 4-O-Substituted Glucuronic Cyclophellitols are Selective Mechanism-Based Heparanase Inhibitors.ChemMedChem · 2023Article
- Synthetic Strategies for FRET-Enabled Carbohydrate Active Enzyme Probes.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Synthesis of Novel Suramin Analogs With Anti-Proliferative ActivityFrontiers in chemistry · 2021Article
- In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis.PLoS neglected tropical diseases · 2020Article
- The anti-parasitic drug suramin potently inhibits formation of seminal amyloid fibrils and their interaction with HIV-1.The Journal of biological chemistry · 2019Article
- The anti-parasitic agent suramin and several of its analogues are inhibitors of the DNA binding protein Mcm10.Open biology · 2019Article
- Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds.iScience · 2019Review
- Polymeric fluorescent heparin as one-step FRET substrate of human heparanase.Carbohydrate polymers · 2019Article
- Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.Acta biomaterialia · 2019Article
- Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype.Frontiers in pharmacology · 2019Review
- The close relationship between heparanase and epithelial mesenchymal transition in gastric signet-ring cell adenocarcinoma.Oncotarget · 2018Article
- Mechanisms of heparanase inhibitors in cancer therapy.Experimental hematology · 2016Review
- The effect of suramin on inhibiting fibroblast proliferation and preventing epidural fibrosis after laminectomy in rats.Journal of orthopaedic surgery and research · 2016Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAberrant expression of heparanase (Hpa) is associated with apoor prognosis in ovarian and cervical cancer patients. Inhibitors of Hpa can prevent the growth and metastasis of malignant tumor cells, and suramin may be such a compound that has strong anti-proliferative effects on several kinds of cancer cells. We have therefore tested whether the growth inhibiting effect of suramin on ovarian and cervical cancer cells is due to downregulation of Hpa expression.
resultsSuramin at 300-600 μg/ml significantly inhibited HO-8910 PM and HeLa cell growth at 24 h, in both a time-dependent and dose-dependent manner, with an IC50 of 320 μg/ml and 475 μg/ml, respectively. Suramin at 300 μg/ml significantly decreased the expression of Hpa mRNA (P < 0.005) and protein (P < 0.005) in both HO-8910 PM and HeLa cells at 48 h.
conclusionsThe inhibitory effect of suramin on Hpa enzyme may be due to downregulating of its expression in cancer cells. These findings confirm the importance of Hpa in tumor growth and the potential clinical application of Hpa inhibitors in the treatment of ovarian and cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.